Health Technology Assessment (HTA) agencies have been widely promoting their interest in taking relevant patient data into account during the drug review process. The effort to make a place for the patient voice in reviews is promising in an economic climate where the cost of innovation is under constant scrutiny. However, it raises two critical questions:
- How much weight does the patient data have in the HTA decision process?
- Are submissions by patient and professional groups associated with positive decisions?